{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:32:43Z","timestamp":1761060763617,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Circassia Ltd"},{"name":"Green Cross Pharmaceuticals"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sun Pharma Advanced Research Corporation"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.anai.2019.03.007","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T12:20:27Z","timestamp":1552479627000},"page":"639-646.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical standardization of two controlled allergen challenge facilities"],"prefix":"10.1016","volume":"122","author":[{"given":"Anne K.","family":"Ellis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark W.","family":"Tenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Steacy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alkis","family":"Togias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles P.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia M.","family":"Visness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia G.","family":"Rather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.anai.2019.03.007_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.anai.2013.07.019","article-title":"Environmental exposure unit: a sensitive, specific, and reproducible methodology for allergen challenge","volume":"111","author":"Ellis","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2019.03.007_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1081-1206(10)61235-5","article-title":"Experimental models for the evaluation of treatment of allergic rhinitis","volume":"96","author":"Day","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2019.03.007_bib3","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jaci.2013.09.051","article-title":"Effect of confounding cofactors on responses to pollens during natural season versus pollen challenge chamber exposure","volume":"133","author":"Jacobs","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2019.03.007_bib4","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/all.13133","article-title":"Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future\u2014an EAACI Position Paper","volume":"72","author":"Pfaar","year":"2017","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2019.03.007_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1081-1206(10)62616-6","article-title":"Environmental exposure unit: a system to test anti-allergic treatment","volume":"83","author":"Day","year":"1999","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2019.03.007_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.anai.2011.04.009","article-title":"Validation of the biogenics research chamber for Juniperus ashei (mountain cedar) pollen","volume":"107","author":"Jacobs","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2019.03.007_bib7","series-title":"Asthma, Allergy, and Inflammation Branch, Division of Allergy, Immunology and Transplantation, NIAID\/NIH. Environmental Exposure Units. Clinical Trial Design for Validation","first-page":"1","author":"Togias","year":"2010"},{"issue":"3","key":"10.1016\/j.anai.2019.03.007_bib8","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaci.2014.10.045","article-title":"Environmental exposure chambers in allergen immunotherapy trials: current status and clinical validation needs","volume":"135","author":"R\u00f6sner-Friese","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2019.03.007_bib9","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/j.1365-2222.2003.01810.x","article-title":"Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis","volume":"33","author":"Krug","year":"2003","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.anai.2019.03.007_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13223-015-0071-3","article-title":"Clinical validation of controlled grass pollen challenge in the Environmental Exposure Unit (EEU)","volume":"11","author":"Ellis","year":"2015","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.anai.2019.03.007_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JAA.S123547","article-title":"Technical and clinical validation of an environmental exposure unit for ragweed","volume":"9","author":"Gomes","year":"2016","journal-title":"J\u00a0Asthma Allergy"},{"issue":"4","key":"10.1016\/j.anai.2019.03.007_bib12","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jaci.2014.09.047","article-title":"Symptom dynamics during repeated serial allergen challenge chamber exposures to house dust mite","volume":"135","author":"Jacobs","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2019.03.007_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaci.2012.03.031","article-title":"Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes","volume":"130","author":"Jacobs","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2019.03.007_bib14","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/j.1365-2222.2010.03498.x","article-title":"Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions","volume":"40","author":"Hohlfeld","year":"2010","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anai.2019.03.007_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2222.2005.00099.x","article-title":"The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper","volume":"6","author":"Day","year":"2006","journal-title":"Clin Exp Allergy Rev"},{"key":"10.1016\/j.anai.2019.03.007_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1472-9733.2008.00133.x","article-title":"Pilot study of Japanese cedar pollen exposure using a novel artificial exposure chamber (OHIO Chamber)","volume":"8","author":"Hashiguchi","year":"2008","journal-title":"Clin Exp Allergy Rev"},{"issue":"2","key":"10.1016\/j.anai.2019.03.007_bib17","first-page":"100","article-title":"Placebo and nocebo effect: a mini-review","volume":"26","author":"Po\u017egain","year":"2014","journal-title":"Psychiatr Danub"},{"issue":"3","key":"10.1016\/j.anai.2019.03.007_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/00029157.2014.976785","article-title":"Placebo and nocebo effects: a complex interplay between psychological factors and neurochemical networks","volume":"57","author":"Frisaldi","year":"2015","journal-title":"Am J Clin Hypn"},{"issue":"2","key":"10.1016\/j.anai.2019.03.007_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1081-1206(10)63104-3","article-title":"Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis","volume":"79","author":"Day","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2019.03.007_bib20","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0091-6749(98)70172-1","article-title":"Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit","volume":"101","author":"Day","year":"1998","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2019.03.007_bib21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S1081-1206(10)62260-0","article-title":"Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system","volume":"87","author":"Day","year":"2001","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2019.03.007_bib22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1368-5031.2004.0117.x","article-title":"Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)","volume":"58","author":"Day","year":"2004","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.anai.2019.03.007_bib23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1081-1206(10)60339-0","article-title":"Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit","volume":"102","author":"Day","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2019.03.007_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1081-1206(10)60494-2","article-title":"Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients","volume":"101","author":"Patel","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2019.03.007_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/iid3.143","article-title":"Technical and clinical validation of the Allergen BioCube(\u00ae) for timothy grass","volume":"5","author":"Angjeli","year":"2017","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"10.1016\/j.anai.2019.03.007_bib26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaci.2016.12.986","article-title":"Clinical validation of a house dust mite environmental challenge chamber model","volume":"140","author":"Zieglmayer","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2019.03.007_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.anai.2010.12.018","article-title":"Anti-allergic drug testing in an environmental challenge chamber is suitable both in and out of the relevant pollen season","volume":"106","author":"Badorrek","year":"2011","journal-title":"Ann Allergy Asthma Immunol"},{"year":"1999","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","author":"Chow","key":"10.1016\/j.anai.2019.03.007_bib28"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619301863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619301863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:21:56Z","timestamp":1761052916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619301863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1081120619301863"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.03.007","relation":{},"ISSN":["1081-1206"],"issn-type":[{"type":"print","value":"1081-1206"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical standardization of two controlled allergen challenge facilities","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}